Archive

New approach to prostate cancer improves 5-year survival

Written by Bruce Sylvester | 26 Jun 2022

A combination of hormone therapy and pelvic lymph node radiation improves survival of prostate cancer patients, researchers reported on May 26, 2022 in The Lancet. “We can now… read more.

Prostate cancer linked to increased risk of venous thromboembolism

Written by Bruce Sylvester | 1 Jun 2022

Researchers from Sweden have reported that, compared with men with no prostate cancer, men diagnosed with prostate cancer have a significantly higher risk of developing venous thromboembolism (VTE)… read more.

Initial treatment choice for prostate cancer doesn’t affect mental health outcomes

Written by Charlie King | 13 Mar 2022

Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology®, an… read more.

Adjuvant darolutamide prolongs survival in metastatic, hormone-sensitive prostate cancer

Written by Bruce Sylvester | 25 Feb 2022

Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic,… read more.

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Written by Charlie King | 24 Feb 2022

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men… read more.

Lantheus receives FDA approval of Pylarify injection, the first and only commercially available PSMA PET imaging agent for prostate cancer

Written by Charlie King | 1 Jun 2021

Lantheus Holdings, Inc. announced that the FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis… read more.

EMA validates MAA for relugolix for the treatment of advanced prostate cancer – Myovant Sciences

Written by Charlie King | 5 Apr 2021

Myovant Sciences announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer. The validation of the… read more.

Translational oncology: Tumour mutational burden and exploitation of DNA repair

Written by Christine Clark | 5 Jul 2019

Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.

ASCO 2017: Adjuvant abiraterone has very significant effect on prostate cancer survival

Written by Karen Ramirez | 14 Aug 2017

Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.

Cancer survival worse in RA patients

Written by Lorraine Carolan | 19 Aug 2016

Survival was more than 2 years shorter in breast, prostate cancers. Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year's EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by Lorraine Carolan | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.